Celera‘s genetic discovery platform has led to many proprietary findings forming the basis for partnerships with diagnostic service labs around the world. Licensed discoveries may be useful for laboratory developed tests that can improve patient outcomes.

Celera is also responsible for licensing certain molecular technologies, such as real-time polymerase chain reaction instrumentation intellectual property. This patent portfolio has been non-exclusively licensed to third parties for use in a various diagnostic applications. Licensees include, for example, Cepheid, Siemens and Beckman Coulter. Additional licenses are available.